ASX Filings

Appendix 3B

May 18, 2016

Change in substantial holding for ANP

May 16, 2016

Opthea Doses First Patient in Ph2A for OPT-302 in Wet AMD

May 5, 2016

Opthea Ph1 wAMD Trial with OPT-302 Meets Primary Objective

April 21, 2016

Change of Director's Interest Notice - GK

April 7, 2016

Change of Director's Interest Notice - MS

April 7, 2016

Change of Director's Interest Notice - MB

April 7, 2016

Opthea Completes Patient Enrolment for Phase 1 wet AMD Trial

March 30, 2016

Chairman's Address to the EGM

March 7, 2016

Results of the Extraordinary General Meeting

March 7, 2016